Managing intractable epilepsy: the role of epilepsy surgery
Intractable epilepsy, more often called drug-resistant epilepsy, describes seizures that persist despite appropriately chosen anti-seizure medicines. International definitions usually require failure of two tolerated regimens, used alone or together. Not every patient is a surgical candidate. For selected people with a well-localised focal cause, surgery can offer seizure freedom or substantial seizure reduction and may restore independence more effectively than continued medication trials.
A surgical decision begins with accurate classification of the seizure type and identification of where the abnormal electrical activity starts. MRI, EEG, medication history, cognitive testing and the patient’s priorities must all fit together. The purpose is not to operate simply because medicines have failed, but to determine whether removing or modulating a defined network offers a benefit that outweighs surgical risk, uncertainty and lifelong follow-up.
| Approach | Where it fits | Potential benefit | Main limitation |
|---|---|---|---|
| Anti-seizure medication | Most newly diagnosed and many chronic epilepsies | Broad availability and reversible treatment | Side effects, adherence issues and incomplete control |
| Resective surgery | Drug-resistant focal epilepsy with a safe, consistent target | Opportunity for seizure freedom | Irreversible risks and possible persistent seizures |
| Neuromodulation | Drug-resistant epilepsy when resection is unsafe or unlikely | Adjustable seizure reduction without tissue removal | Usually palliative, with ongoing device care and follow-up |
When surgery becomes relevant
Medication remains the foundation of epilepsy care, but repeated failures can carry costs beyond seizure frequency. Ongoing seizures may cause injury, sleep disruption, workplace restrictions, driving concerns and strain on family life. Side effects from multiple medicines can also affect cognition and mood. A comprehensive review should therefore consider function, safety and quality of life alongside the number of events recorded in a seizure diary.
Features that support surgical assessment include focal seizures with a consistent onset, a structural abnormality on MRI, a reliable seizure pattern and tests that agree about the responsible area. Some patients have hippocampal sclerosis or another lesion that can be removed. Children with certain cortical developmental disorders may also benefit from surgery, sometimes before medicines produce durable control.
The presence of a lesion does not guarantee that removing it will stop the seizures, and surgery may be inappropriate when localisation is unsafe, seizures arise from several independent areas or the suspected region supports essential functions. Some operations are intended to reduce seizure burden rather than eliminate it. The expected benefit must always be matched to the individual patient rather than a general success rate.
Building a reliable diagnosis
Localisation depends on the pattern of events as well as test results. In Australian neurology practice, patients are commonly asked to bring a current “seizure diary” recording seizure type, duration, triggers and medication timing. Video recordings can reveal features that are difficult to identify from a verbal description, particularly the onset of focal impaired-awareness seizures or movements that might otherwise be mistaken for other events.
MRI of the brain looks for structural causes, while scalp EEG records abnormal electrical activity. Long-term or video-EEG monitoring may be needed to capture habitual seizures and distinguish them from non-epileptic events. Neither investigation is perfect on its own: a normal EEG does not exclude epilepsy, and a suspicious scan does not prove that a lesion causes the seizures.
When the available evidence conflicts, further testing may include neuropsychological assessment, language and memory evaluation, functional imaging, Wada testing or invasive stereo-EEG monitoring. Not every patient requires invasive recordings. Results are interpreted by a multidisciplinary team that includes neurologists, neurosurgeons, neuropsychologists, nurses and EEG specialists, with the patient and family contributing to the goals of assessment.
Choosing between resection and neuromodulation
When a single focus can be removed safely, resective surgery offers the strongest possibility of seizure freedom. Procedures include lesionectomy, temporal lobectomy, selective amygdalohippocampectomy and hemispherectomy. The operation is selected according to the location, extent of abnormal tissue and functions that must be preserved. Some centres offer laser interstitial thermal therapy or stereotactic radiofrequency treatment as alternatives to conventional removal.
Neuromodulation is considered when there is no safe removable target or when the epileptic network is too widespread. Vagus nerve stimulation, deep brain stimulation and responsive neurostimulation work differently and suit different seizure patterns. They generally aim to reduce seizures and improve quality of life rather than guarantee freedom. Device selection also depends on local expertise, follow-up capacity, medical history and personal preference.
Age, general health, language skills, memory, comorbidities and reproductive plans can affect the choice and timing of surgery. A person with substantial impairment from frequent seizures may have different priorities from someone whose seizures are less frequent but more dangerous. Shared decision-making should consider whether the proposed benefit matches the life the patient wants to regain, not merely whether an operation is technically possible.
Understanding benefit and risk
No single percentage describes the likely outcome for every patient with drug-resistant epilepsy. Seizure freedom is more likely when investigations consistently identify one focus, the surrounding tissue is relatively healthy and the planned operation can remove that area. When localisation is uncertain or bilateral independent onsets are present, meaningful seizure reduction may be the more realistic aim. Even successful surgery does not guarantee that medication can be discontinued.
Potential complications include bleeding, infection, cerebrospinal fluid leakage, seizures, weakness, language impairment and changes in memory or mood. Rare but serious events such as stroke can also occur. Device procedures have their own risks, including infection, lead or generator problems and revision surgery. These issues should be discussed openly, including how the team would respond if the first operation did not achieve the expected result.
Recovery may involve an acute stay in hospital, rehabilitation and a gradual return to work, study or driving. Antiseizure medicines should not be stopped without specialist supervision, even when seizures stop. Staged procedures may be needed when the target and the required treatment can be defined more safely in separate stages. Psychological support and realistic goal-setting are important because the effects of epilepsy often extend well beyond the operating theatre.
Moving forward through Australian care
A common Australian pathway begins with a GP referral and a Medicare-supported review by a neurologist. Public patients generally move through hospital clinics and may wait for specialist assessment or elective surgery, while private neurology and neurosurgical services can offer greater scheduling flexibility. Medicare rebates do not necessarily cover the full cost of private treatment, so fees, likely investigations and potential periods away from work should be discussed before referral.
Complex epilepsy surgery is concentrated in tertiary centres, including programs in Melbourne, Sydney, Brisbane and Perth. Paediatric assessments may involve services such as the Royal Children’s Hospital Melbourne or a specialist children’s network elsewhere. For regional and remote families, travel, accommodation and repeated attendance can be substantial burdens. Telehealth can help with history review and long-distance follow-up, although EEG recording, MRI and formal cognitive testing usually require attendance in person.
Ongoing medicines may be subsidised through the Pharmaceutical Benefits Scheme, while neurological devices and some investigations can still attract out-of-pocket costs. Therapeutic Goods Administration approval does not necessarily mean a device will be funded or available at every centre. A written estimate of likely expenses is sensible before committing to a private pathway, particularly when staged surgery or prolonged rehabilitation may be required.
Clinicians, patients and families can explore the open clinical case discussions before making a referral, and registered members can post, reply and subscribe to updates. If drug-resistant epilepsy is affecting daily life, begin with a comprehensive neurologist review, organise the seizure diary and medication history, and ask whether a tertiary epilepsy-surgical assessment should be included in the care plan.